GAITHERSBURG, Md. and SHANGHAI, China , March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results